The 2026 Lipid Science Prize is awarded to Prof. Jens Juul Holst by Camurus Lipid Research Foundation – Kåre Larsson och Gunnar Sandbergs forskningsstiftelse
Lund, Sweden – 10 February 2026 – Camurus Lipid Research Foundation – Kåre Larsson och Gunnar Sandbergs forskningsstiftelse – announced today that the 2026 Lipid Science Prize is awarded to Professor Jens Juul Holst at the Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences at the University of Copenhagen, Denmark.
Dr. Jens Juul Holst receives the award in recognition of his significant contributions to the discovery and characterisation of glucagon-like peptide-1 (GLP-1). This gastrointestinal hormone has been shown to be essential in stimulating insulin release, regulating blood glucose levels, and influencing both appetite and food intake. Jens Juul Holst has also been actively engaged in the development of novel pharmaceuticals, collaborating with colleagues to pioneer new treatments for type 2 diabetes and obesity—therapies that now benefit millions of people worldwide.
The Lipid Science Prize, including an award of SEK 500 000, will be presented to Professor Jens Juul Holst at a ceremony during the Annual Lipid Science Symposium on Tuesday, 21 April 2026 at Hypoteket in Lund, Sweden.
In addition to the main prize, two junior researchers will also be honoured at this event:
Dr. Milka Doktorova, Stockholm University, Sweden for her research on biomembrane structure and dynamics, combining modelling and experimental techniques. She has studied the structure-function relationship of asymmetric biological lipid membranes and their interaction with membrane proteins. The results of these studies are important for our understanding of cell function mechanisms.
Dr. Jon Pallbo Arvidsson, Lund University, Sweden for his research on peptide-lipid interaction of relevance for the amyloid formation, which is related to neurodegeneration such as Alzheimer’s and Parkinson’s disease. His work concerned defining conditions where amyloid formation occur or could be inhibited.